TY - JOUR
T1 - Options for imaging cellular therapeutics in vivo
T2 - a multi-stakeholder perspective
AU - Helfer, Brooke M.
AU - Ponomarev, Vladimir
AU - Patrick, P. Stephen
AU - Blower, Philip J.
AU - Feitel, Alexandra
AU - Fruhwirth, Gilbert O.
AU - Jackman, Shawna
AU - Pereira Mouriès, Lucilia
AU - Park, Margriet V.D.Z.
AU - Srinivas, Mangala
AU - Stuckey, Daniel J.
AU - Thu, Mya S.
AU - van den Hoorn, Tineke
AU - Herberts, Carla A.
AU - Shingleton, William D.
N1 - Funding Information:
This work was supported by the HESI CT-TRACS Committee. HESI is a non-profit scientific organization that facilitates public and private partnerships in human and environmental health. MP's contribution was partly funded by the European Union's Horizon 2020 research and innovation program under the nTRACK project (grant no. 761031).
Funding Information:
This work was supported by the HESI CT-TRACS Committee. HESI is a non-profit scientific organization that facilitates public and private partnerships in human and environmental health. MP's contribution was partly funded by the European Union's Horizon 2020 research and innovation program under the nTRACK project (grant no. 761031). BMH, SJ, MS, MST and WDS are employees of companies developing cellular therapies, providing testing or enabling technologies for the manufacture of cellular therapies. Conception and design of the study: BMH, VP, AF, LPM, MS, TvdH, CAH and WDS. Analysis and interpretation of data: BMH, VP, PSP, PJB, AF, GOF, SJ, LPM, MVDZP, MS, DJS, MST, TvdH, CAH, WDS. Drafting or revising the manuscript: BMH, VP, PSP, PJB, AF, GOF, SJ, LPM, MVDZP, MS, DJS, MST, TvdH, CAH, WDS. All authors have approved the final article. The authors thank all members (volunteers) of the HESI CT-TRACS Committee for their valuable time and expert input in the discussions leading to this article. The authors also thank Ms Christina West for manuscript review and editorial support.
Publisher Copyright:
© 2021 International Society for Cell & Gene Therapy
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9
Y1 - 2021/9
N2 - Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible explanation for this is that additional tools and technologies to enable their development have only recently become available. To support the safety evaluation of cell therapies, the Health and Environmental Sciences Institute Cell Therapy—Tracking, Circulation and Safety Committee, a multisector collaborative committee, polled the attendees of the 2017 International Society for Cell & Gene Therapy conference in London, UK, to understand the gaps and needs that cell therapy developers have encountered regarding safety evaluations in vivo. The goal of the survey was to collect information to inform stakeholders of areas of interest that can help ensure the safe use of cellular therapeutics in the clinic. This review is a response to the cellular imaging interests of those respondents. The authors offer a brief overview of available technologies and then highlight the areas of interest from the survey by describing how imaging technologies can meet those needs. The areas of interest include imaging of cells over time, sensitivity of imaging modalities, ability to quantify cells, imaging cellular survival and differentiation and safety concerns around adding imaging agents to cellular therapy protocols. The Health and Environmental Sciences Institute Cell Therapy—Tracking, Circulation and Safety Committee believes that the ability to understand therapeutic cell fate is vital for determining and understanding cell therapy efficacy and safety and offers this review to aid in those needs. An aim of this article is to share the available imaging technologies with the cell therapy community to demonstrate how these technologies can accomplish unmet needs throughout the translational process and strengthen the understanding of cellular therapeutics.
AB - Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible explanation for this is that additional tools and technologies to enable their development have only recently become available. To support the safety evaluation of cell therapies, the Health and Environmental Sciences Institute Cell Therapy—Tracking, Circulation and Safety Committee, a multisector collaborative committee, polled the attendees of the 2017 International Society for Cell & Gene Therapy conference in London, UK, to understand the gaps and needs that cell therapy developers have encountered regarding safety evaluations in vivo. The goal of the survey was to collect information to inform stakeholders of areas of interest that can help ensure the safe use of cellular therapeutics in the clinic. This review is a response to the cellular imaging interests of those respondents. The authors offer a brief overview of available technologies and then highlight the areas of interest from the survey by describing how imaging technologies can meet those needs. The areas of interest include imaging of cells over time, sensitivity of imaging modalities, ability to quantify cells, imaging cellular survival and differentiation and safety concerns around adding imaging agents to cellular therapy protocols. The Health and Environmental Sciences Institute Cell Therapy—Tracking, Circulation and Safety Committee believes that the ability to understand therapeutic cell fate is vital for determining and understanding cell therapy efficacy and safety and offers this review to aid in those needs. An aim of this article is to share the available imaging technologies with the cell therapy community to demonstrate how these technologies can accomplish unmet needs throughout the translational process and strengthen the understanding of cellular therapeutics.
KW - biodistribution
KW - cell therapy
KW - fate
KW - in vivo tracking
KW - non-invasive
KW - safety
UR - http://www.scopus.com/inward/record.url?scp=85103700781&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2021.02.005
DO - 10.1016/j.jcyt.2021.02.005
M3 - Review article
AN - SCOPUS:85103700781
SN - 1465-3249
VL - 23
SP - 757
EP - 773
JO - CYTOTHERAPY
JF - CYTOTHERAPY
IS - 9
ER -
